UY28558A1 - Proteína - Google Patents

Proteína

Info

Publication number
UY28558A1
UY28558A1 UY28558A UY28558A UY28558A1 UY 28558 A1 UY28558 A1 UY 28558A1 UY 28558 A UY28558 A UY 28558A UY 28558 A UY28558 A UY 28558A UY 28558 A1 UY28558 A1 UY 28558A1
Authority
UY
Uruguay
Prior art keywords
protein
carboxylation
subjected
range
glutamylcarboxylase
Prior art date
Application number
UY28558A
Other languages
English (en)
Inventor
Christel Fenge
Ann Lovgren
Anders Thelin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29559260&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY28558(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY28558A1 publication Critical patent/UY28558A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invención se refiere a métodos y herramientas para producir grandes cantidades de proteína sometida a carboxilación gama que comprende: (i) cultivar una célula adaptada para expresar una proteína que requiere carboxilación gama y glutamilcarboxilasa y en una proporción de al menos 10:1, bajo condiciones apropoadas para la expresión de ambas proteínas, y (ii) aislar la proteína sometida a carboxilación gama.
UY28558A 2003-10-14 2004-10-13 Proteína UY28558A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0324044.7A GB0324044D0 (en) 2003-10-14 2003-10-14 Protein

Publications (1)

Publication Number Publication Date
UY28558A1 true UY28558A1 (es) 2005-05-31

Family

ID=29559260

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28558A UY28558A1 (es) 2003-10-14 2004-10-13 Proteína

Country Status (29)

Country Link
US (2) US7842477B2 (es)
EP (2) EP2292748B1 (es)
JP (1) JP4658946B2 (es)
KR (1) KR101201020B1 (es)
CN (2) CN1867669B (es)
AR (1) AR046180A1 (es)
AT (1) ATE491789T1 (es)
AU (2) AU2004281350B2 (es)
BR (1) BRPI0415277A (es)
CA (1) CA2541764C (es)
CO (1) CO5690657A2 (es)
DE (1) DE602004030603D1 (es)
DK (1) DK1678297T3 (es)
ES (2) ES2532470T3 (es)
GB (1) GB0324044D0 (es)
HK (1) HK1155475A1 (es)
IL (2) IL174633A (es)
IS (1) IS8447A (es)
MX (1) MXPA06004060A (es)
MY (1) MY141859A (es)
NO (1) NO339740B1 (es)
NZ (2) NZ546584A (es)
PL (1) PL1678297T3 (es)
PT (1) PT1678297E (es)
RU (2) RU2372401C2 (es)
TW (1) TWI355419B (es)
UY (1) UY28558A1 (es)
WO (1) WO2005038019A1 (es)
ZA (1) ZA200603038B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006101474A1 (en) * 2005-03-15 2006-09-28 University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
EP2336360A1 (en) * 2003-09-23 2011-06-22 University Of North Carolina At Chapel Hill Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin K epoxide reductase gene and warfarin dosage
GB0324044D0 (en) 2003-10-14 2003-11-19 Astrazeneca Ab Protein
EP1874928A1 (en) 2005-04-13 2008-01-09 AstraZeneca AB A host cell comprising a vector for production of proteins requiring gamma-carboxylation
CA2624072A1 (en) * 2005-09-30 2007-04-12 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Process for producing recombinant human thrombin by cultured cell
US7745484B2 (en) 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
DK1969127T4 (en) * 2005-12-21 2017-10-16 Cnj Holdings Inc Process for the preparation of biologically active vitamin K-dependent proteins by recombinant methods
RU2008139428A (ru) * 2006-03-06 2010-05-20 Хьюмэджин, Инк. (Us) Способ получения рекомбинантного тромбина и фибриногена человека
JP6050927B2 (ja) * 2007-04-26 2016-12-21 シーエヌジェイ ホールディングス，インコーポレイテッド 高シアル酸含量を有する組換えビタミンｋ依存性タンパク質およびその調製方法
US8206967B2 (en) * 2007-07-06 2012-06-26 Medimmune Limited Method for production of recombinant human thrombin
AU2011313505B2 (en) * 2010-10-06 2015-09-17 Medimmune Limited Factor II and fibrinogen for treatment of haemostatic disorders
US9631002B2 (en) 2010-12-21 2017-04-25 The University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin K-dependent proteins
WO2013036445A1 (en) 2011-09-06 2013-03-14 Medimmune Llc Methods for processing coagulation factors
RU2500816C1 (ru) * 2012-07-19 2013-12-10 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК рАК380, КОДИРУЮЩАЯ ПОЛИПЕПТИД РЕКОМБИНАНТНОГО ФАКТОРА IХ СВЕРТЫВАЕМОСТИ КРОВИ ЧЕЛОВЕКА, ЛИНИЯ КЛЕТОК Cricetulus griseus CHO 1E6 - ПРОДУЦЕНТ РЕКОМБИНАНТНОГО ФАКТОРА IХ СВЕРТЫВАЕМОСТИ КРОВИ ЧЕЛОВЕКА И СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА, ОБЛАДАЮЩЕГО АКТИВНОСТЬЮ РЕКОМБИНАНТНОГО ФАКТОРА IХ
JP5830486B2 (ja) 2013-03-29 2015-12-09 シスメックス株式会社 組換えバキュロウイルスおよびその利用
PL3083677T3 (pl) * 2013-12-20 2020-03-31 Novartis Ag Nowe komórki eukariotyczne i sposoby rekombinowanej ekspresji produktu będącego przedmiotem zainteresowania
CN109207462B (zh) * 2018-08-01 2021-05-11 深圳市新产业生物医学工程股份有限公司 异常凝血酶原及其制备方法和包含其的检测剂、试剂盒及应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3043857A1 (de) 1980-11-21 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ii und vii
US4599308A (en) * 1981-10-06 1986-07-08 Hamer Dean H Protein from SV40 recombinants
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
JPH01502080A (ja) 1986-11-17 1989-07-27 ニュー・イングランド・メディカル・センター 組み換えビタミンｋ依存性蛋白質のガンマカルボキシル化の増強
US6224864B1 (en) 1986-12-03 2001-05-01 Pharmacia & Upjohn Company Antibiotic 10381A, and process for the preparation of anitbiotics 10381B
WO1989012685A1 (en) 1987-05-18 1989-12-28 Integrated Genetics, Inc. Improved protein c molecules and method for making and activating same
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
US5118614A (en) 1988-01-18 1992-06-02 Tessek Sdruzeni Praha Concentrates of coagulation factors ii, vii, ix and x, method of their preparation and use
AU8427091A (en) 1990-07-23 1992-02-18 Zymogenetics Inc. Gamma-carboxylase and methods of use
US5965789A (en) 1991-01-11 1999-10-12 American Red Cross Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
US5268275A (en) 1991-05-08 1993-12-07 The University Of North Carolina At Chapel Hill Vitamin K-dependent carboxylase
US5219995A (en) 1992-07-14 1993-06-15 Alpha Therapeutic Corporation Plasma fraction purification
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5639661A (en) * 1994-03-23 1997-06-17 The University Of Iowa Research Foundation Genes and proteins for treating cystic fibrosis
DE4430204A1 (de) 1994-08-26 1996-02-29 Behringwerke Ag Arzneimittel, welches als Gegenmittel für Blut-Antikoagulanzien geeignet ist und seine Verwendung
EP0796623B1 (de) 1996-03-20 2005-05-25 Baxter Aktiengesellschaft Pharmazeutisches Präparat zur Behandlung von Blutgerinnungsstörungen
DE69841459D1 (en) * 1997-02-14 2010-03-11 American Nat Red Cross Expression des active human factor ix im brustdrüsengewebe transgener tiere
CA2315879A1 (en) 1997-12-24 1999-07-08 Immunex Corporation V201 dna and polypeptides
US6413737B1 (en) 1999-07-09 2002-07-02 Cohesion Technologies, Inc. Ecarin prothrombin protease and methods
WO2001007068A1 (en) 1999-07-23 2001-02-01 Case Western Reserve University Novel methods and reagents for the treatment of osteoarthritis
AU2001268373A1 (en) * 2000-06-13 2001-12-24 The Children's Hospital Of Philadelphia Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus
BR0114374A (pt) 2000-10-02 2003-12-30 Novo Nordisk As Preparação compreendendo uma pluralidade de polipeptìdeos de fator vii, métodos para a determinação do padrão de glicoforma de fator vii e de polipeptìdeos relacionados com fator vii, e para a produção da dita preparação, formulação farmacêutica, métodos para o tratamento de uma sìndrome responsiva a fator vii, para a prevenção de sangramento indesejado, para a prevenção de coagulação sanguìnea indesejada, e para prevenção de reações mediadas por fator de tecido, e, uso da preparação
CN100347297C (zh) 2001-07-06 2007-11-07 财团法人化学及血清疗法研究所 利用基因工程技术制备人凝血酶的方法
JP4150814B2 (ja) 2001-07-06 2008-09-17 財団法人化学及血清療法研究所 遺伝子組換えエカリン及びその製造方法
CA2452395C (en) 2001-07-10 2012-04-10 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Pharmaceutically stable hemostatic compositions
EP2336360A1 (en) 2003-09-23 2011-06-22 University Of North Carolina At Chapel Hill Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin K epoxide reductase gene and warfarin dosage
GB0324044D0 (en) 2003-10-14 2003-11-19 Astrazeneca Ab Protein
ES2344413T3 (es) 2003-10-14 2010-08-26 Baxter International Inc. Polipeptido vkorc1 de reciclaje de la vitamina k-epoxido, una diana terapeutica de la cumarina y sus derivados.
EP1676911B1 (en) 2003-10-24 2010-04-21 Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute Novel recombinant animal cells with high protein production, method of constructing the same and method of mass protein production using the same
EP1831363A1 (en) 2004-12-21 2007-09-12 Novo Nordisk Health Care AG Expression of gamma-carboxylated polypeptides in gamma-carboxylation deficient host systems
EP1874928A1 (en) 2005-04-13 2008-01-09 AstraZeneca AB A host cell comprising a vector for production of proteins requiring gamma-carboxylation
EP1963506B1 (en) 2005-12-02 2010-10-27 Wake Forest University Health Sciences Compositions and methods for increasing production of recombinant gamma-carboxylated proteins
DK1969127T4 (en) 2005-12-21 2017-10-16 Cnj Holdings Inc Process for the preparation of biologically active vitamin K-dependent proteins by recombinant methods
US8206967B2 (en) 2007-07-06 2012-06-26 Medimmune Limited Method for production of recombinant human thrombin

Also Published As

Publication number Publication date
DK1678297T3 (da) 2011-03-14
EP2292748A1 (en) 2011-03-09
NZ546584A (en) 2009-08-28
ATE491789T1 (de) 2011-01-15
CN1867669A (zh) 2006-11-22
CA2541764A1 (en) 2005-04-28
IL174633A0 (en) 2006-08-20
NZ578306A (en) 2011-02-25
JP4658946B2 (ja) 2011-03-23
TWI355419B (en) 2012-01-01
US8697440B2 (en) 2014-04-15
PL1678297T3 (pl) 2011-11-30
TW200523365A (en) 2005-07-16
US20050164367A1 (en) 2005-07-28
WO2005038019A1 (en) 2005-04-28
AU2008205445A1 (en) 2008-09-04
MXPA06004060A (es) 2006-06-28
EP1678297A1 (en) 2006-07-12
CN1867669B (zh) 2011-10-19
CN102443548B (zh) 2014-03-12
EP1678297B1 (en) 2010-12-15
ES2532470T3 (es) 2015-03-27
BRPI0415277A (pt) 2006-12-19
IL226313A0 (en) 2013-06-27
HK1155475A1 (en) 2012-05-18
MY141859A (en) 2010-07-16
KR20060123152A (ko) 2006-12-01
GB0324044D0 (en) 2003-11-19
AU2004281350A1 (en) 2005-04-28
NO339740B1 (no) 2017-01-30
RU2006110147A (ru) 2007-11-20
RU2009123931A (ru) 2010-12-27
US20110092429A1 (en) 2011-04-21
AR046180A1 (es) 2005-11-30
CA2541764C (en) 2015-03-31
CN102443548A (zh) 2012-05-09
DE602004030603D1 (de) 2011-01-27
AU2004281350B2 (en) 2008-05-15
US7842477B2 (en) 2010-11-30
ES2357603T3 (es) 2011-04-28
NO20061470L (no) 2006-05-12
RU2372401C2 (ru) 2009-11-10
EP2292748B1 (en) 2014-12-17
CO5690657A2 (es) 2006-10-31
PT1678297E (pt) 2011-03-15
IL174633A (en) 2013-06-27
JP2007508820A (ja) 2007-04-12
ZA200603038B (en) 2007-09-26
KR101201020B1 (ko) 2012-11-14
IS8447A (is) 2006-05-10

Similar Documents

Publication Publication Date Title
UY28558A1 (es) Proteína
EP3486314A3 (en) Placental stem cell populations
NZ569543A (en) Means and methods for influencing the stability of antibody producing cells
WO2006127809A3 (en) Methods for expansion and analysis of cultured hematopoietic stem cells
WO2006105152A3 (en) Amnion-derived cell compositions, methods of making and uses thereof
ATE514755T1 (de) Fluoreszenzfarbstoffe zur verwendung bei der glukoseerfassung
ATE384119T1 (de) Isoprenoidproduktion
MY163480A (en) Sclerostin binding agents
WO2006017134A3 (en) Preprimitive streak and mesendoderm cells
ATE502997T1 (de) Oberflächenaktive peroxycarbonsäurezusammensetzungen
DE60232234D1 (de) Verfahren zur kultivierung von circovirus
BRPI0508628A (pt) conjugados de hidroxialquil amido e uma proteìna
AR047440A1 (es) Produccion de un anticuerpo monoclonal en un hongo heterocarion o una celula huesped fungal
NO20081622L (no) Fremgangsmater for produksjon av proteiner ved anvendelse av anti-senescence forbindelser
DE602006017878D1 (de) Nachweis fötaler zellen aus mütterlichem blut
AU2019268061A1 (en) Placental stem cell populations
ATE456666T1 (de) Verfahren zur auswertung von ribonukleotidsequenzen
ATE463559T1 (de) Zelllinie zur produktion von coronaviren
MEP56408A (en) Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes
AR046435A1 (es) Metodo para la preparacion de productos de queseria que contienen soja, de alta calidad
EP2341147A3 (en) Preprimitive streak and mesendoderm cells
ATE363490T1 (de) Methode zur produktion monoklonaler antikörper
ATE464289T1 (de) Neues verfahren zur herstellung von thoc
WO2004072262A3 (en) Cultured cd14+ antigen presenting cells
ES2190771B2 (es) Procedimiento para la produccion de resveratrol en cultivos celulares.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170516